290 related articles for article (PubMed ID: 26341922)
1. Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma.
Misiewicz-Krzeminska I; Sarasquete ME; Vicente-Dueñas C; Krzeminski P; Wiktorska K; Corchete LA; Quwaider D; Rojas EA; Corral R; Martín AA; Escalante F; Bárez A; García JL; Sánchez-García I; García-Sanz R; San Miguel JF; Gutiérrez NC
Clin Cancer Res; 2016 Jan; 22(1):207-17. PubMed ID: 26341922
[TBL] [Abstract][Full Text] [Related]
2. Cyclin D1 positive multiple myeloma: predominance of the short, 3'UTR-deficient transcript is associated with high cyclin D1 mRNA levels in cases with t(11;14) translocation, but does not correlate with proliferation rate or genomic deletions.
Slotta-Huspenina J; Koch I; Richter M; Bink K; Kremer M; Specht K; Krugmann J; Quintanilla-Martinez L; Fend F
Leuk Res; 2008 Jan; 32(1):79-88. PubMed ID: 17629555
[TBL] [Abstract][Full Text] [Related]
3. LncRNA HOTAIR Regulates CCND1 and CCND2 Expression by Sponging miR-206 in Ovarian Cancer.
Chang L; Guo R; Yuan Z; Shi H; Zhang D
Cell Physiol Biochem; 2018; 49(4):1289-1303. PubMed ID: 30205383
[TBL] [Abstract][Full Text] [Related]
4.
Martín-Garcia D; Navarro A; Valdés-Mas R; Clot G; Gutiérrez-Abril J; Prieto M; Ribera-Cortada I; Woroniecka R; Rymkiewicz G; Bens S; de Leval L; Rosenwald A; Ferry JA; Hsi ED; Fu K; Delabie J; Weisenburger D; de Jong D; Climent F; O'Connor SJ; Swerdlow SH; Torrents D; Beltran S; Espinet B; González-Farré B; Veloza L; Costa D; Matutes E; Siebert R; Ott G; Quintanilla-Martinez L; Jaffe ES; López-Otín C; Salaverria I; Puente XS; Campo E; Beà S
Blood; 2019 Feb; 133(9):940-951. PubMed ID: 30538135
[TBL] [Abstract][Full Text] [Related]
5. MiR-146a-5p inhibits cell proliferation and cell cycle progression in NSCLC cell lines by targeting CCND1 and CCND2.
Li YL; Wang J; Zhang CY; Shen YQ; Wang HM; Ding L; Gu YC; Lou JT; Zhao XT; Ma ZL; Jin YX
Oncotarget; 2016 Sep; 7(37):59287-59298. PubMed ID: 27494902
[TBL] [Abstract][Full Text] [Related]
6. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.
Bergsagel PL; Kuehl WM; Zhan F; Sawyer J; Barlogie B; Shaughnessy J
Blood; 2005 Jul; 106(1):296-303. PubMed ID: 15755896
[TBL] [Abstract][Full Text] [Related]
7. Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cells.
Katayama Y; Sakai A; Okikawa Y; Oue N; Asaoku H; Sasaki A; Imanaka F; Tsujimoto T; Takimoto Y; Masuda R; Nakaju N; Otsuki T; Yasui W; Kimura A
Int J Oncol; 2004 Sep; 25(3):579-95. PubMed ID: 15289859
[TBL] [Abstract][Full Text] [Related]
8. Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity.
Tiedemann RE; Mao X; Shi CX; Zhu YX; Palmer SE; Sebag M; Marler R; Chesi M; Fonseca R; Bergsagel PL; Schimmer AD; Stewart AK
J Clin Invest; 2008 May; 118(5):1750-64. PubMed ID: 18431519
[TBL] [Abstract][Full Text] [Related]
9. Identification of cyclin D1 mRNA overexpression in B-cell neoplasias by real-time reverse transcription-PCR of microdissected paraffin sections.
Specht K; Kremer M; Müller U; Dirnhofer S; Rosemann M; Höfler H; Quintanilla-Martinez L; Fend F
Clin Cancer Res; 2002 Sep; 8(9):2902-11. PubMed ID: 12231535
[TBL] [Abstract][Full Text] [Related]
10. Epigenetically altered miR-193b targets cyclin D1 in prostate cancer.
Kaukoniemi KM; Rauhala HE; Scaravilli M; Latonen L; Annala M; Vessella RL; Nykter M; Tammela TL; Visakorpi T
Cancer Med; 2015 Sep; 4(9):1417-25. PubMed ID: 26129688
[TBL] [Abstract][Full Text] [Related]
11. CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma.
Salaverria I; Royo C; Carvajal-Cuenca A; Clot G; Navarro A; Valera A; Song JY; Woroniecka R; Rymkiewicz G; Klapper W; Hartmann EM; Sujobert P; Wlodarska I; Ferry JA; Gaulard P; Ott G; Rosenwald A; Lopez-Guillermo A; Quintanilla-Martinez L; Harris NL; Jaffe ES; Siebert R; Campo E; Beà S
Blood; 2013 Feb; 121(8):1394-402. PubMed ID: 23255553
[TBL] [Abstract][Full Text] [Related]
12. Protein Expression for Novel Prognostic Markers (Cyclins D1, D2, D3, B1, B2, ITGβ7, FGFR3, PAX5) Correlate With Previously Reported Gene Expression Profile Patterns in Plasma Cell Myeloma.
Mansoor A; Akhter A; Pournazari P; Mahe E; Shariff S; Farooq F; Elyamany G; Shahbani-Rad MT; Rashid-Kolvear F
Appl Immunohistochem Mol Morphol; 2015; 23(5):327-33. PubMed ID: 25265432
[TBL] [Abstract][Full Text] [Related]
13. 3'UTR mediated regulation of the cyclin D1 proto-oncogene.
Deshpande A; Pastore A; Deshpande AJ; Zimmermann Y; Hutter G; Weinkauf M; Buske C; Hiddemann W; Dreyling M
Cell Cycle; 2009 Nov; 8(21):3592-600. PubMed ID: 19823025
[TBL] [Abstract][Full Text] [Related]
14. Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome.
Ngo BT; Felthaus J; Hein M; Follo M; Wider D; Ihorst G; Engelhardt M; Wäsch R
Leuk Lymphoma; 2010 Sep; 51(9):1632-42. PubMed ID: 20578819
[TBL] [Abstract][Full Text] [Related]
15. Mantle cell lymphomas with low levels of cyclin D1 long mRNA transcripts are highly proliferative and can be discriminated by elevated cyclin A2 and cyclin B1.
Sander B; Flygare J; Porwit-Macdonald A; Smith CI; Emanuelsson E; Kimby E; Liden J; Christensson B
Int J Cancer; 2005 Nov; 117(3):418-30. PubMed ID: 15900590
[TBL] [Abstract][Full Text] [Related]
16. Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma.
Alvarez-Benayas J; Trasanidis N; Katsarou A; Ponnusamy K; Chaidos A; May PC; Xiao X; Bua M; Atta M; Roberts IAG; Auner HW; Hatjiharissi E; Papaioannou M; Caputo VS; Sudbery IM; Karadimitris A
Nat Commun; 2021 Sep; 12(1):5450. PubMed ID: 34521827
[TBL] [Abstract][Full Text] [Related]
17. Discovery and characterization of a novel CCND1/MRCK gene fusion in mantle cell lymphoma.
Masamha CP; Albrecht TR; Wagner EJ
J Hematol Oncol; 2016 Mar; 9():30. PubMed ID: 27025456
[TBL] [Abstract][Full Text] [Related]
18. Frequency and distribution of trisomy 11 in multiple myeloma patients: relation with overexpression of CCND1 and t(11;14).
Guglielmelli T; Giugliano E; Cappia S; Papotti M; Saglio G
Cancer Genet Cytogenet; 2007 Feb; 173(1):51-6. PubMed ID: 17284370
[TBL] [Abstract][Full Text] [Related]
19. Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma.
Yang L; Wang H; Kornblau SM; Graber DA; Zhang N; Matthews JA; Wang M; Weber DM; Thomas SK; Shah JJ; Zhang L; Lu G; Zhao M; Muddasani R; Yoo SY; Baggerly KA; Orlowski RZ
Oncogene; 2011 Mar; 30(11):1329-40. PubMed ID: 21057542
[TBL] [Abstract][Full Text] [Related]
20. The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma.
Choudhury SR; Ashby C; Tytarenko R; Bauer M; Wang Y; Deshpande S; Den J; Schinke C; Zangari M; Thanendrarajan S; Davies FE; van Rhee F; Morgan GJ; Walker BA
J Hematol Oncol; 2020 Aug; 13(1):108. PubMed ID: 32762714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
